kabutan

Tsubota Laboratory Incorporated(4890) Summary

4890
TSE Growth
Tsubota Laboratory Incorporated
316
JPY
+1
(+0.32%)
Jan 29, 3:30 pm JST
2.06
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
314.1
Jan 29, 3:23 pm JST
Summary Chart Historical News Financial Result
PER
54.3
PBR
6.31
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
321 JPY 2.09 USD
Previous Close Jan 28
315 JPY 2.06 USD
High Jan 29, 9:00 am
321 JPY 2.09 USD
Low Jan 29, 9:39 am
313 JPY 2.04 USD
Volume
19,200
Trading Value
6.00M JPY 0.04M USD
VWAP
315.0 JPY 2.06 USD
Minimum Trading Value
31,600 JPY 206 USD
Market Cap
8.15B JPY 0.05B USD
Number of Trades
50
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
140
1-Year High Apr 22, 2025
3,725
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 607,100
Jan 16, 2026 0 579,800
Jan 9, 2026 0 575,800
Dec 26, 2025 0 833,000
Dec 19, 2025 0 530,300
Company Profile
Tsubota Laboratory Incorporated is a biotech venture originating from Keio University. The company focuses on research and development of pharmaceuticals for myopia, dry eye, presbyopia, and brain activation.
Sector
Pharmaceuticals
Tsubota Laboratory Incorporated, a biotech venture born out of Keio University School of Medicine, aims to create groundbreaking innovations in the treatment of myopia, dry eye, presbyopia, and brain-related disorders. The company conducts advanced research in collaboration with affiliated universities and pursues joint development with partner companies to evaluate research outcomes. Its business model is based on generating revenue through joint research and development agreements, licensing agreements, upfront payments, milestone payments, and post-commercialization royalties, which are then reinvested into new research in a cyclical manner. A distinctive feature of the company is its research and development utilizing the high-level expertise of external contracted researchers. Tsubota Laboratory Incorporated adopts a dual strategy, simultaneously developing and marketing pharmaceuticals and medical devices alongside commodity products.